Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
about
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEtidronate for treating and preventing postmenopausal osteoporosisDrugs in development: bisphosphonates and metalloproteinase inhibitorsEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesReview of risedronate in the treatment of osteoporosisThe effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancerThe effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women.Current and potential future drug treatments for osteoporosis.Etidronate and alendronate in the treatment of postmenopausal osteoporosis.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Diagnosis and treatment of osteoporosis.Management of primary osteoporosis.Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability.The gastrointestinal tolerability and safety of oral bisphosphonates.Medical treatment of vertebral osteoporosisEffects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.Management of established osteoporosisChanges in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogensEtidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty.Managing elderly people's osteoporosis. Why? Who? How?The therapeutic use of bisphosphonates.Use of bisphosphonates in the management of postmenopausal osteoporosis.Bisphosphonates: mechanisms of action.Osteoporosis and the jaws: questions remain to be answered.Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?The future of ipriflavone in the management of osteoporotic syndromes.Beware of surrogate outcome measures.Bisphosphonates: preclinical aspects and use in osteoporosis.Bone mass measurements: reasons to be cautious.Prevention of osteoporotic fractures--should orthopedic surgeons care?Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases.Effects of antiresorptive treatment on nonvertebral fracture outcomes.Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year follow-up of four patients.Seven years of treatment with risedronate in women with postmenopausal osteoporosis.Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
P2860
Q24242665-D55B1811-DC0A-4ACB-B602-902B6A08BA3FQ24244995-BECA57E9-6C0F-47FA-B75E-8E6B04774635Q24795847-5D69F4AE-1A2D-45CB-B8D0-FDC98BCD6E2CQ24802074-C9AAF8EA-043C-4230-A798-D4DAD1CA09E8Q28192294-CCFEB039-3F3B-47E5-BB95-C027C43CA0B2Q28362960-98829A7D-FEC8-4B44-B0C3-DB4ABF63DDCFQ33185235-99A32ECA-882B-46C5-A6AC-4A3FCDBCB31FQ33579316-BD089232-356C-48A7-86BD-294B53A8F06CQ33659364-3053E318-7620-4C26-9925-A006CDB96FDCQ34300668-62B658ED-30A0-46D4-9F25-83C4C9FC65EAQ34520972-40B593F4-38DC-4A89-A26F-CE464EA3C2EDQ35047919-3898CCE3-FA88-4E9A-98F8-13C29DAAF22FQ35095225-81518696-DDFF-4BF2-9345-6F6CFA390A79Q35188424-E93C3397-AF9F-4E39-A3F6-4B29ADFC5E22Q35194544-DB3D6D9B-63D0-4C63-B3AF-F8A92661D5CAQ35299212-490EBB5F-383B-48E6-9BF3-5E4FBBBEC229Q35547940-638DFABB-0E28-4261-B0BE-0865E64A3A70Q35775369-382252AD-F358-4C94-8B22-C60C011F3424Q35802137-1748F16C-3FDD-4F42-9001-AB4AE5B7E18DQ35954529-19E11983-5B34-4AFC-9890-FB7759C4196AQ36044183-5B28E927-A12C-41F0-AEE8-6708EFF54280Q36116123-3151DDD0-ADA2-4F96-BD95-BB3B907E905BQ36440568-93ED73AD-967E-4974-A354-65D21EFB1D7AQ36577705-7724DFF9-2230-4C22-B1E8-7A7E233E59B1Q36886733-4D83BB43-3951-485F-915A-DE25E9ADA2DFQ37800181-73F2C13D-1F8F-4937-B47A-4F67FC5DC382Q39766013-B5E7B5F7-1E98-4135-80CE-FEF96E5D7A0DQ40525950-C97C00F3-3E7F-420D-9D8F-DB7F5C22CF72Q40867107-B6E57DB0-990B-4402-8860-EB70A9559E76Q40911840-9684584A-C08A-4D66-826D-77DE877F1B60Q41033018-4B37ACED-08B2-42EE-95ED-F0B02942E029Q41387009-D5016337-3BB2-45D4-B11C-2FCB67C75D24Q42573249-CE5FE241-353B-4708-9A24-EE90EF4F7C6CQ43749300-A304F84C-51E5-40B7-AA0C-20C090CCE332Q43776261-5A5BC111-45B3-4E93-81CB-5ADC7382D311Q44488735-90E0BCC8-1355-4A46-939D-BBD609AE183EQ44650580-B26E0F9E-0368-4857-A5BB-400A6589F601Q44715973-53386706-34B1-493C-9884-03004FE08EC2Q45083822-C5C29B06-8990-40D7-B924-AF02C7724BB5Q45105237-D1DF7184-0AB4-4A74-957A-4AAF30BCF7E8
P2860
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Four-year study of intermitten ...... d by one year of open therapy.
@en
Four-year study of intermitten ...... d by one year of open therapy.
@nl
type
label
Four-year study of intermitten ...... d by one year of open therapy.
@en
Four-year study of intermitten ...... d by one year of open therapy.
@nl
prefLabel
Four-year study of intermitten ...... d by one year of open therapy.
@en
Four-year study of intermitten ...... d by one year of open therapy.
@nl
P2093
P1476
Four-year study of intermitten ...... d by one year of open therapy.
@en
P2093
A A Licata
C H Chesnut
H K Genant
P D Miller
R D Jackson
R D Wasnich
S T Harris
P304
P356
10.1016/0002-9343(93)90350-X
P407
P577
1993-12-01T00:00:00Z